Studies how semaglutide affects brown fat activity in people with obesity
Measures brown fat activity before and during semaglutide treatment in adults with obesity.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 1 Feb 2023
- Planned end
- 1 Feb 2026
- Type of study
- Observational
- Treatments tested
- Semaglutide Injectable Product (not provided by the study)
- Record updated
- 11 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men and post-menopausal women who are about to start semaglutide for weight loss. The study does not provide the drug.
- Age
- Over 18 years
- Sex
- Men and post-menopausal women
- Earlier treatment
- People must be scheduled to start semaglutide for weight loss. Prior neck surgery or neck irradiation is not allowed.
Main reasons for not taking part
- Prior neck surgery or neck irradiation
- Use of beta blocker medicines or any other glucose lowering medicine
- Diabetes or nerve disorders such as diabetic neuropathy
- Abnormal thyroid function, cancer, or significant chronic, kidney, liver or hormone disease
- Current smokers
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
- >18 years of age and willing to participate
- Male or post-menopausal females
Who cannot take part
- History of prior neck surgery and /or neck irradiation; Use of beta blocker agents; Use of any other glucose lowering medication; History of neuropathic disorders (e.g. diabetic neuropathy); Diabetic patients; Individuals without normal thyroid function; Individuals with cancer; Any significant chronic disease or renal, hepatic or endocrine disease; Current smokers; Inability of patient to provide consent either for medical reasons or psychiatric reasons
Where in United States
- UCLA HealthLos Angeles, United StatesContact: Julie Sorg, MSNTaking people
About the trial
What the trial wants to find out
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role.
Read full original descriptionShow less
We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
Treatments tested
- Semaglutide Injectable Product (not provided by the study)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
- Plain-language title
- Studies how semaglutide affects brown fat activity in people with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 May 2025